Original Article: Evaluation of blood pressure in pediatric survivors of acute lymphoblastic leukemia and healthy children; A case-control study


1 Department of Basic and Laboratory Sciences, Khomein University of Medical Sciences, Khomein

2 Clinical Research Development Center of Amirkabir Hospital, Arak University of Medical Sciences, Arak

3 Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan

4 Department of Pediatric Cardiology, Arak University of Medical Sciences, Arak, Iran


Background: The exact prevalence of hypertension in children surviving acute lymphoblastic leukemia (ALL) has not been fully estimated. The aim of this study was to investigate the prevalence of arterial hypertension (AH) and to determine the risk factors for the development of AH in children surviving ALL with current treatments. Materials and Methods: A total of 150 patients (84 males, 66 females, with an age range of 1–16 years) were included in the study. Demographic and clinical information of patients were initially recorded. Hypertension is defined as average systolic blood pressure (BP) and/or diastolic BP that is greater than the 95th percentile for gender, age, and height. Results: The mean age at the assessment of BP was 11.3 and 9.8 years in the ALL and control group, respectively. A total of 20.6% of survivors of ALL and 10% of controls had high BP. Most patients in both groups had normal BP (65.3% patients in ALL group and 75.4% subjects in the control group). The number of patients with hypertension was significantly higher in ALL patients as compared with the control group (P = 0.026). Conclusion: The prevalence of AH in children surviving ALL is higher than in children in the general population, which emphasizes the need for regular monitoring of BP in children surviving ALL and intervention in the lifestyle of this population. Careful follow-up of BP status is warranted for long-term survivors of childhood cancer.


Seiler A, Jenewein J. Resilience in cancer patients. Front Psychiatry 2019;10:208.  Back to cited text no. 1
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.  Back to cited text no. 2
Dastgiri S, Fozounkhah S, Shokrgozar S, Taghavinia M, Asvadi Kermani A. Incidence of leukemia in the Northwest of Iran. Health Promot Perspect 2011;1:50-3.  Back to cited text no. 3
Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: A review. Environ Health Perspect 2007;115:138-45.  Back to cited text no. 4
Ghasemi A, Rostami S, Chahardouli B, Alizad Ghandforosh N, Ghotaslou A, Nadali F. Study of SFRP1 and SFRP2 methylation status in patients with de novo acute myeloblastic leukemia. Int J Hematol Oncol Stem Cell Res 2015;9:15-21.  Back to cited text no. 5
Alizad Ghandforoush N, Chahardouli B, Rostami S, Ghadimi H, Ghasemi A, Alimoghaddam K, et al. Evaluation of minimal residual disease in acute myeloid leukemia with NPM1 marker. Int J Hematol Oncol Stem Cell Res 2016;10:147-52.  Back to cited text no. 6
Ghasemi A, Nadali F, Chahardouli B, Ghandforosh NA, Zadeh AG, Rostami S. Study of correlation between SFRP-1 and SFRP-2 hypermethylation with relapse, complete remission, genetic mutations of FLT3-ITD and NPM1 and immunophenotypes of leukemic cells in patients with de novo acute myeloblastic leukemia. J Hematol 2014;3:34-42.  Back to cited text no. 7
Ghasemi A, Ghotaslou A, Mohammadi M, Abbasian S, Ghaffari K. Methylation of the Wnt signaling antagonist, Wnt inhibitory factor 1 and dickkopf-1 genes in acute myeloid leukemia at the time of diagnosis. Zahedan J Res Med Sci 2016;18:1-6.  Back to cited text no. 8
Ghasemi A, Ghotaslou A, Ghaffari K, Mohammadi M. Methylation status of SOX17 and RUNX3 genes in acute leukemia. Iran J Blood Cancer 2015;7:213-9.  Back to cited text no. 9
Ghasemi A, Ghotaslou A, Mohammadi M, Ghaffari K, Abbasian S. Dysregulation of the WNT signaling pathway through methylation of Wnt inhibitory factor 1 and dickkopf-1 genes among AML patients at the time of diagnosis. Iran J Blood Cancer 2014;7:11-7.  Back to cited text no. 10
Ofran Y, Izraeli S. BCR-ABL (Ph)-like acute leukemia-pathogenesis, diagnosis and therapeutic options. Blood Rev 2017;31:11-6.  Back to cited text no. 11
Ghaffari K, Ghasemi A, Mohammadi M, Abbasian S. Comparison of secreted frizzled-related protein-4 &-5 promoter methylation in patients with acute myeloblastic leukemia and healthy individuals. Iran J Blood Cancer 2021;13:1-5.  Back to cited text no. 12
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol 2013;14:199-209.  Back to cited text no. 13
Veringa SJ, van Dulmen-den Broeder E, Kaspers GJ, Veening MA. Blood pressure and body composition in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2012;58:278-82.  Back to cited text no. 14
Levy E, Samoilenko M, Morel S, England J, Amre D, Bertout L, et al. Cardiometabolic risk factors in childhood, adolescent and young adult survivors of acute lymphoblastic leukemia – A petale cohort. Sci Rep 2017;7:17684.  Back to cited text no. 15
Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham heart study: A cohort study. Lancet 2001;358:1682-6.  Back to cited text no. 16
Gostynski M, Gutzwiller F, Kuulasmaa K, Döring A, Ferrario M, Grafnetter D, et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes Relat Metab Disord 2004;28:1082-90.  Back to cited text no. 17
Dossus L, Kaaks R. Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab 2008;22:551-71.  Back to cited text no. 18
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.  Back to cited text no. 19
Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 2005;153:81-9.  Back to cited text no. 20
Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Clin Oncol 2003;21:1359-65.  Back to cited text no. 21
Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006;107:1303-12.  Back to cited text no. 22
Van Dongen-Melman JE, Hokken-Koelega AC, Hählen K, De Groot A, Tromp CG, Egeler RM. Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 1995;38:86-90.  Back to cited text no. 23
Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Clin Oncol 2008;26:4639-45.  Back to cited text no. 24
Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia – From the St. Jude Lifetime Cohort. Br J Haematol 2014;165:364-74.  Back to cited text no. 25
Koch VH, Colli A, Saito MI, Furusawa EA, Ignes E, Okay Y, et al. Comparison between casual blood pressure and ambulatory blood pressure monitoring parameters in healthy and hypertensive adolescents. Blood Press Monit 2000;5:281-9.  Back to cited text no. 26
Baillargeon J, Langevin AM, Lewis M, Grady JJ, Thomas PJ, Mullins J, et al. Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. Cancer 2005;103:1725-9.  Back to cited text no. 27
Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, et al. Height and weight in children treated for acute lymphoblastic leukemia: Relationship to CNS treatment. J Clin Oncol 2003;21:2953-60.  Back to cited text no. 28
Frese EM, Fick A, Sadowsky HS. Blood pressure measurement guidelines for physical therapists. Cardiopulm Phys Ther J 2011;22:5-12.  Back to cited text no. 29
World Health Organization. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension: Guidelines subcommittee. J Hypertens 1999;17:151-83.  Back to cited text no. 30
Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 2007;110:2313-20.  Back to cited text no. 31
Falkner B, Daniels SR. Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Hypertension 2004;44:387-8.  Back to cited text no. 32
Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002;28:195-214.  Back to cited text no. 33
Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869-73.  Back to cited text no. 34
Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: The Muscatine Study. Pediatrics 1989;84:633-41.  Back to cited text no. 35
Menghetti E, Strisciuglio P, Spagnolo A, Carletti M, Paciotti G, Muzzi G, et al. Hypertension and obesity in Italian school children: The role of diet, lifestyle and family history. Nutr Metab Cardiovasc Dis 2015;25:602-7.  Back to cited text no. 36
Xi B, Li H, Li S, Mi J. Recent prevalence of hypertension among Chinese children and adolescents based on 2010 China national blood pressure references. Int J Cardiol 2014;174:870-1.  Back to cited text no. 37
Moradmand S, Ganji MR, Meysami AP, Akbari Z, Mirkhani SZ, Tabrizchi N, et al. Prevalence of hypertension and its impact on birth weight and current body weight in school children in Tehran. J Payavard Salamat 2012;5:16-23.  Back to cited text no. 38
Kelishadi R, Razaghi EM, Gouya MM, Ardalan G, Gheiratmand R, Delavari A, et al. Association of physical activity and the metabolic syndrome in children and adolescents: CASPIAN study. Horm Res Paediatr 2007;67:46-52.  Back to cited text no. 39
Ociepa T, Bartnik M, Zielezińska K, Urasiński T. Prevalence and risk factors for arterial hypertension development in childhood acute lymphoblastic leukemia survivors. J Pediatr Hematol Oncol 2019;41:175-80.  Back to cited text no. 40
Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman DL. Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56:372-8.  Back to cited text no. 41
Oeffinger KC. Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer 2008;50:462-7.  Back to cited text no. 42
Meacham LR, Chow EJ, Ness KK, Kamdar KY, Chen Y, Yasui Y, et al. Cardiovascular risk factors in adult survivors of pediatric cancer – A report from the childhood cancer survivor study. Cancer Epidemiol Prev Biomarkers 2010;19:170-81.  Back to cited text no. 43
Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG. Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol 2005;15:202-6.